Antihypertensive Class Labeling On Trial Outcomes Data To Be Assessed
Executive Summary
FDA's Cardiovascular & Renal Drugs Advisory Committee will address the generalizability of clinical outcome trials for antihypertensive drug products at its June 15 meeting
You may also be interested in...
Hypertension Rx Labels Should Include Product-Specific CV Data – Cmte.
Data on antihypertensives that have shown cardiovascular endpoint benefits in well-controlled trials should be included in labeling, FDA and the Cardiovascular & Renal Drugs Advisory Committee agreed at a June 15 meeting
Hypertension Rx Labels Should Include Product-Specific CV Data – Cmte.
Data on antihypertensives that have shown cardiovascular endpoint benefits in well-controlled trials should be included in labeling, FDA and the Cardiovascular & Renal Drugs Advisory Committee agreed at a June 15 meeting
NIH Hypertension Guidelines Suggest Newer Agents For Certain Risk Factors
Hypertensive patients with certain comorbidities should begin therapy with drugs that have demonstrated effectiveness for those conditions, updated clinical guidelines from NIH's National Heart, Lung & Blood Institute states